Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02286089 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
A Phase 1 study of Age-related Macular Degeneration, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 7
- Study locations
NCT02286089 is a Phase 1 study of Age-related Macular Degeneration that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 24 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT02286089, a Phase 1 study of Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
Conditions Studied
Interventions
- BIOLOGICAL OpRegen
Study Locations (7)
Other
- Hadassah Medical Center - Jerusalem
- Rabin Medical Center - Petah Tikva
- Kaplan Medical Center - Rehovot
- Tel Aviv Sourasky Medical Center - Tel Aviv
California
- West Coast Retina Medical Group - San Francisco
Ohio
- Cincinnati Eye Institute - Cincinnati
Pennsylvania
- Mid Atlantic Retina - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-04-01 |
| Est. Completion | 2031-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02286089
The ClinicalTrials.gov registry entry for NCT02286089 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which OpRegen is the first listed.
NCT02286089 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT02286089 about?
NCT02286089 is a clinical study titled "Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration". The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease p...
What is the current status of trial NCT02286089?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-04-01. Estimated completion is 2031-01-31.
What conditions does trial NCT02286089 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT02286089?
The interventions under investigation include: OpRegen (BIOLOGICAL).
Who is sponsoring clinical trial NCT02286089?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02286089 being conducted?
This trial has 7 study locations across California, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.